Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas.
Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significant increase in research directed towards identifying potential biomarkers that can be used to diagnose and provide prognostic information for pancreatic cancer. These markers can be used clinically to optimize and personalize therapy for individual patients. In this review, we focused on 3 biomarkers involved in the DNA damage response pathway and the necroptosis pathway: Chromodomain-helicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinase domain-like protein. The aim of this article is to review present literature provided for these biomarkers and current studies in which their effectiveness as prognostic biomarkers are analyzed in order to determine their future use as biomarkers in clinical medicine. Based on the data presented, these biomarkers warrant further investigation, and should be validated in future studies.
Crystal S Seldon, David S Yu, Jerome C Landry, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States.
Crystal S
CS
Seldon
Crystal S Seldon, David S Yu, Jerome C Landry, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States.
Lauren E
LE
Colbert
Crystal S Seldon, David S Yu, Jerome C Landry, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States.
William A
WA
Hall
Crystal S Seldon, David S Yu, Jerome C Landry, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States.
Sarah B
SB
Fisher
Crystal S Seldon, David S Yu, Jerome C Landry, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States.
David S
DS
Yu
Crystal S Seldon, David S Yu, Jerome C Landry, Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, United States.
Jerome C
JC
Landry
Biomarker; Chromodomain-helicase-DNA binding protein 5; Chromodomain-helicase-DNA binding protein 7; Mixed lineage kinase domain-like protein; Pancreatic adenocarcinoma